604 related articles for article (PubMed ID: 25759019)
1. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Sharpe HJ; Pau G; Dijkgraaf GJ; Basset-Seguin N; Modrusan Z; Januario T; Tsui V; Durham AB; Dlugosz AA; Haverty PM; Bourgon R; Tang JY; Sarin KY; Dirix L; Fisher DC; Rudin CM; Sofen H; Migden MR; Yauch RL; de Sauvage FJ
Cancer Cell; 2015 Mar; 27(3):327-41. PubMed ID: 25759019
[TBL] [Abstract][Full Text] [Related]
2. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
[No Abstract] [Full Text] [Related]
4. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
Ridky TW; Cotsarelis G
Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
[TBL] [Abstract][Full Text] [Related]
5. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
6. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
7. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
8. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
Metcalfe C; de Sauvage FJ
Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
[TBL] [Abstract][Full Text] [Related]
10. Smoothened mutations underlie Basal cell carcinoma resistance.
Cancer Discov; 2015 May; 5(5):OF9. PubMed ID: 25813347
[No Abstract] [Full Text] [Related]
11. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
12. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
[TBL] [Abstract][Full Text] [Related]
13. Hedgehog signaling in basal cell carcinoma.
Otsuka A; Levesque MP; Dummer R; Kabashima K
J Dermatol Sci; 2015 May; 78(2):95-100. PubMed ID: 25766766
[TBL] [Abstract][Full Text] [Related]
14. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
16. Smoothened inhibitors in the treatment of advanced basal cell carcinomas.
Kunstfeld R
Curr Opin Oncol; 2014 Mar; 26(2):184-95. PubMed ID: 24469022
[TBL] [Abstract][Full Text] [Related]
17. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
Ruiz Salas V; Alegre M; Garcés JR; Puig L
Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
[TBL] [Abstract][Full Text] [Related]
18. Advanced treatment for basal cell carcinomas.
Atwood SX; Whitson RJ; Oro AE
Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
[TBL] [Abstract][Full Text] [Related]
19. Sonidegib phosphate: new approval for basal cell carcinoma.
Tibes R
Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
[TBL] [Abstract][Full Text] [Related]
20. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]